SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of SGT-003’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for SGT-003 is expected to reach an annual total of $255 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

SGT-003 Overview

SGT-003 is under development for the treatment of Duchenne muscular dystrophy (DMD).  It is administered through intravenous route. It comprises of adeno associated virus delivering nNOS-containing microdystrophin.

Solid Biosciences Overview

Solid Biosciences, operates as a life science company that develops therapies for duchenne muscular dystrophy (DMD). The company product pipeline includes SGT-003, AVB-202-TT and AVB-401 BAG3 DCM. Its pipeline treats duchenne, friedreich’s ataxia and mediated dilated cardiomyopathy. Biosciences has development programs across scientific platforms which include corrective therapies, disease-modifying therapies, disease understanding and assistive devices. The company works in collaboration with the University of Massachusetts Medical School, The Duchenne Research Fund, University of Washington, Alex’s Wish. It has operations across the US. Solid Biosciences is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$8.1 million for the fiscal year ended December 2022 (FY2022), a decrease of 40.6% over FY2021. The operating loss of the company was US$88.2 million in FY2022, compared to an operating loss of US$72.3 million in FY2021. The net loss of the company was US$86 million in FY2022, compared to a net loss of US$72.2 million in FY2021.

For a complete picture of SGT-003’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.